A meta-analysis concluded that combining a biomarker blood test with ultrasound increased the detection of early-stage liver cancer by as much as 40 percent.
Investigators will use Biocept's liquid biopsy tests to detect ALK rearrangements both at baseline and to monitor treatment response and resistance mechanisms.
